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Abstract
Bacteria are capable of expressing a diverse range of cell surface polysaccharides from capsules and
lipopolysaccharides through teichoic acid molecules to lipoarabinomannans. This review will focus on
the expression of capsular polysaccharides and their interaction with the host. In particular, it will
focus on the role of capsular polysaccharides as immunomodulatory molecules.
Introduction and context
The polysaccharide capsule coats the outside of the
bacterial cell and as a consequence plays an intimate role
in mediating interactions between the bacterium and its
immediate environment. A capsule is a discrete structure
that is defined as a layer of polysaccharide that either is
physically attached to, or remains tightly associated with,
the cell surface of the bacterium. This is in contrast to
slime, which has a loose association with the surface of
the bacterium and often is shed in large amounts into the
surrounding environment.
Major recent advances
Capsules and interactions with the host
From the pioneering experiments of Griffith on encap-
sulation in pneumococci [1] there is a considerable body
of data indicating that encapsulation is an absolute
requirement for effective systemic infection by human
and animal pathogens [2]. For many years, the perceived
role of the capsule in these diseases was resistance to host
innate defences, in particular resistance to complement-
mediated killing and phagocystosis [3–5]. Recent studies
have indicated that, in both cases, the capsule is
predicted to function as a shield masking underlying
cell surface structures [6]. As such, encapsulation reduces
both the generation and effectiveness of the membrane
attack complex and the level of opsonisation. In
addition, terminal sialic acid residues on the capsular
polysaccharides of group B streptococci (GBS) have been
shown to mediate interactions with sialic acid-binding
immunoglobulin-like lectins (Siglecs) on the surface
of neutrophils and monocytes [7]. This interaction is
dependent on the extent of O-acetylation of the sialic
acid [7]. Engagement of Siglecs on the cell surface of
leukocytes is believed to suppress T-cell signalling [8]
and natural killer cell toxicity [9]. As such, the interaction
between sialic acids on the GBS capsule and Siglecs could
represent an interaction between the microbe and the
host which effectively dampens down both the innate
and adaptive immune responses.
Capsules have also been shown to be essential for
efficient adhesion to host cells. The adhesion of group A
streptococci to pharyngeal cells is mediated via the
interaction between the hyaluronic acid capsule and
CD44, the hyaluronic acid-binding protein [10]. This
interaction between microbe and host induces a signal-
ling pathway that promotes the efficient paracellular
penetration of the mucosal epithelial layer and invasion
of the underlying tissue [10]. Similarly, both the
Escherichia coli K1 capsule and the Neisseria meningitidis
group B capsule have been shown to be important in
intracellular survival and as such may be important in
traversing epithelial and endothelial barriers [11,12].
Capsules as signalling molecules
While capsules undoubtedly function in a shielding
capacity to resist innate defences, there is increasing
evidence that capsular polysaccharides may possess
immunomodulatory activities. These properties
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cells in order to maximise bacterial colonisation, as well
as affecting leukocyte activation to promote the survival
of bacteria within the host. This is perhaps not surprising
considering the location of capsular polysaccharides on
the outermost surface of the bacterial cell. There are
several examples of the immunomodulatory effects of
purified capsular polysaccharides from a range of
pathogenic organisms. In the case of Staphyloccocus
aureus, both capsular polysaccharide types 5 and 8 were
able to bind to epithelial cells and induce interleukin
(IL)-8 expression in addition to inducing IL-8, IL-6,
IL-1b, and tumour necrosis factor-alpha from monocytes
[13]. It was proposed that these capsular polysaccharides
were acting as adhesins to promote attachment to
epithelial cells whilst at t h es a m et i m ee x p r e s s i n g
immunomodulatory effects [13]. Likewise, the purified
type 2 capsular polysaccharide of Streptococcus suis has
been shown to induce monocyte chemoattractant
protein-1 (MCP-1) production from monocytes via a
TLR2/MyD88 (Toll-like receptor-2/myeloid differentia-
tion factor-88)-independent pathway [14]. The serotype
K1 capsular polysaccharide from the oral pathogen
Porphyromonas gingivalis also elicits MCP-1 secretion,
as well as MIP-2 (macrophage inflammatory protein-2)
and RANTES (regulated on activation, normal T-cell
expressed and secreted) from murine macrophages. It
has also been shown to stimulate macrophage migration
[15]. The ability of the purified K1 capsular polysacchar-
ide to induce inflammatory chemokines would suggest
that the capsular polysaccharide is involved in generating
the inflammatory lesions typical of periodontal disease
as a consequence of P. gingivalis infection [15].
In contrast, in Salmonella enterica serovar Typhi (S. typhi),
the Vi capsular antigen reduces TLR-dependent IL-8
production from intestinal mucosa [16] and IL-17
secretion [17]. This indicates that in this case the Vi
antigen is acting to reduce intestinal inflammation,
possibly playing a role in reducing the influx of
neutrophils to the site of infection and thereby promot-
ing the increased survival of S. typhi [16,17]. Indeed, it
has been speculated that the Vi capsule may contribute
to the evasion of the adaptive immune response by
disrupting TLR signalling [18]. Most strikingly, the
purified polysaccharide A from the gut symbiont
Bacteroides fragilis has been shown to have potent anti-
inflammatory properties [19]. Administration of the
polysaccharide was capable of preventing inflammatory
disease in mice infected with Helicobacter hepaticus [19].
This anti-inflammatory response required IL-10-produ-
cing CD4
+ T-cells and demonstrates how a cell surface
polysaccharide could be playing a key role in mediating
microbe-host interactions and preventing the induction
of an inappropriate inflammatory response as a con-
sequence of the colonisation of a gut symbiont [19].
Therefore, it is clear that certain capsular polysaccharides
may be endowed with potent immunomodulatory
properties above and beyond any role they may fulfil
in either shielding the bacterium or promoting adhesion.
Future directions
The role of capsular polysaccharides as signalling
molecules in contributing to the interplay between
microbe and the host puts a new perspective on the
age-old question of capsule diversity. A big question that
remains unanswered is what drives capsule diversity in
an organism such as the pneumococcus. One possibility
is that chemically diverse capsular polysaccharides will
interact differently with the host in terms of chemokine/
cytokine induction. This interaction could range from
neutral (no induction) to either end of the inflammatory
spectrum. As a consequence, the expression of different
capsular polysaccharides may induce a different dialogue
between the microbe and the host, in which case,
different capsular polysaccharides may confer a selective
advantage in different human hosts, depending on the
local mucosal environment they encounter. It is impor-
tant to remember that, with many bacterial pathogens,
disease is the atypical state and is a result of an imbalance
in the fine interplay with the host. Continued colonisa-
tion and the quiet life of the commensal are often the
goal, and it is possible that capsular polysaccharides play
important roles in maintaining the dialogue between
host and microbe and in stabilising this equilibrium.
When considering the interaction between capsular
polysaccharides and the host, the level and regulation
of in vivo expression of capsules will be vital, and
understanding this is an exciting challenge.
Capsular polysaccharides have long been used as
effective vaccine candidates. However, the observation
that capsular polysaccharides have immunomodulatory
properties offers the opportunity to use purified capsular
polysaccharides as pharmacological agents to intervene
in and manipulate the host response in a range of disease
scenarios. The huge diversity of capsular polysaccharides
in the microbiome offers a route to engineer poly-
saccharides with the desired pharmacological properties.
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